We usually take vendor-sponsored surveys with a grain of salt because of inherent bias, but a new one from SAP is interesting enough to merit a mention.
The German software company recently engaged Oxford Economics to survey 120 healthcare professionals from Europe and North America to get a sense of where they are in the realm of precision and personalized medicine.
Naturally, there’s definitely some thinly veiled sales language in the report: “Technology is at the heart of the shift to personalized medicine. Substantial investments in Big Data and analytics are ongoing; a focus on specialized and basic IT capabilities is essential to success.”
Still, there are plenty of useful tidbits. Notably, a lot of providers and research organizations see promise in personalized medicine for emerging neurological treatments. The same goes for cancer, spurred, at least in the U.S., by the new Cancer Moonshot 2020 project and the Obama administration’s Precision Medicine Initiative.
There’s also a glimmer of hope for people with rare diseases. “Personalized medicine is also being applied with increasing frequency to so-called orphan diseases, including rare cancers, which often do not attract as much attention from researchers, yet in aggregate take a large toll in terms of mortality,” the report noted.
Take a look at this infographic from SAP for more results:
